|
Fig 1
RARγ1 is required for the expression of mesoderm markers. (A-D) Embryos were microinjected unilaterally at the 2-cell or 4-cell stage with 3.3 ng RARγ1.S+3.3 ng RARγ1.L/S MOs (Fig. S3). Injected side is to the right of the dashed line, and is indicated by the magenta β-gal lineage tracer. WISH shows that RARγ1 MOs result in the loss of T, fgf8, wnt8 and gdf3. (E-H) Embryos were microinjected unilaterally at the 2-cell or 4-cell stage with 6.6 ng RARα2 MOs (Janesick et al., 2013). Injected side is to the right of the dashed line, and is indicated by the magenta β-gal lineage tracer. RARα2 MOs did not affect T, wnt8 or gdf3 expression, but did produce loss of N-tubulin as previously published (Janesick et al., 2013). All embryos, except in H, are shown in vegetal view at stage 10.5/11. H is shown in dorsal view, with anterior on the bottom at stage 14. Fractions represent the portion of embryos displaying the phenotype. NC, no change.
|
|
Fig 2
Results of RNA-seq data analysis. (A) GO analysis of differentially expressed genes after TTNPB treatment. GO terms shown to be statistically over-represented (P=0.001) in 1 µM TTNPB-treated embryos (q<0.05, FPKMVEH>0.1) conducted in DAVID (Huang da et al., 2009a, b). Gene symbols from Xenopus were used as input, and GO terms were derived from human (for better annotation). Enrichment score is measured by Fisher's exact statistics by the DAVID server. *zic1 is a downregulated gene, and zeb2, tgif2 are <1.5-fold activated by TTNPB. (B) TTNPB-induced genes selected for further analysis in mesoderm development. Activation by TTNPB (represented as log2FPKM) is mapped for both .L and .S subgenomes (Matsuda et al., 2015; Session et al., 2016). kielin and btg2 are not found in .S and .L, respectively; hapln.S is not detected by RNA-seq.
|
|
Fig 3
RAR-selective agonist TTNPB modulates expression of genes identified by RNA-seq. (A-P) WISH from embryos treated at stage 6/7 with 1 μM TTNPB or control vehicle (0.1% ethanol). (A-D,I-L) Control expression of znf703, znf503, kremen2, mamdc2, skida1, nkx6-2, dhh and cyp26a1. (E-H,M-P) TTNPB expands expression of these genes. All embryos are shown in vegetal view at stage 10.5/11 with dorsal lip at the top. N, number of embryos scored in the experiment; 100% of embryos displayed the phenotype shown.
|
|
Fig 4
RARγ1 acts as a transcriptional activator in rescuing znf703 expression in RARγ1 MO embryos. (A-H) Embryos injected unilaterally at the 2- or 4-cell stage. Injected side is to the right of the dashed line, and is indicated by the magenta β-gal lineage tracer. (A,E) 3.3 ng RARγ1.S+3.3 ng RARγ1.L/S MOs diminish znf703 expression. (B,F) VP16-RARγ1 mRNA (0.2 ng) rescues and expands znf703 expression beyond its usual boundary. (C,D,G,H) WT RARγ1 mRNA (0.5 ng) partially rescues znf703 (C,G) and 2 ng DN-RARγ1 mRNA does not rescue znf703 at all, and the severity of the knockdown is increased (D,H). Embryos are shown at stage 10.5/11 in vegetal (A-D) or dorsal (E-H) view. Fractions represent the portion of embryos displaying the phenotype.
|
|
Fig 5
RARγ1 MO inhibits cell adhesion in animal caps. (A-C) Embryos were injected bilaterally at the 2-cell stage with 3.3 ng RARγ1.S+3.3 ng RARγ1.L/S MOs. Animal caps were harvested at stage 9 and incubated in control vehicle or defined doses of activin (0.8, 4, 20 and 100 ng/ml) overnight. (A,B) RARγ1 MOs result in animal cap dissociation (note the large number of single cells) (B), compared with control MO (A) in all treatment conditions. This effect was replicated in three separate experiments. mRNA was harvested 8 h after treatment from the third and final animal cap experiment and evaluated as shown in C. (C) ncam1 expression was significantly reduced in RARγ1 MO animal caps compared with control MO, despite constant housekeeping (histone H4) expression. The upper y-axis represents ncam1 expression 2−ΔCt values normalized to histone H4. The bottom y-axis shows raw Ct values of histone H4.
|
|
Fig 6
RARγ1 knockdown yields a complex phenotype on myod mRNA and Myod protein. Embryos were injected unilaterally at 2- or 4-cell stage. (A) Injection of 3.3 ng RARγ1.S+3.3 ng RARγ1.L/S MOs lead to reduced Myod mRNA expression (10/14 embryos, dorsal view). (B) RARγ1 MOs cause loss of PSM expression of Myod protein and ectopic expression in the trunk of coronal sections of stage 26 embryos (4/4 embryos). (C) RARγ1 MOs cause loss and disorganization of mature somite marker 12/101 in coronal sections of stage 26 embryos (4/4 embryos).
|
|
Supplemental Figure S1. RARγ1 is required for the expression of mesoderm markers.
Embryos were microinjected unilaterally at the 2-cell or 4-cell stage with 10ng RARγ.L/S MO (see Fig S3). Injected side is to the right of the dotted line, and is indicated by the turquoise β-gal lineage tracer. RARγ1 MO results in the loss of T (Brachyury) and Foxa4.
|
|
Supplemental Figure S2. Whole mount in situ hybridization showing the expression of Rarγ,Aldh1a2, and Cyp26a1 at stage 10.5/11, vegetal view, dorsal lip at the top.
|
|
Supplemental Figure S3. Specificity of RARγ1 MO phenotype. Two different morpholinos were designed to target Xenopus laevis Rarγ1. (Top) Mapping of MOs to the .S and .L subgenomes (Session, 2016). MO#1 matches nearly perfectly to both .S and .L, whereas MO #2 matches only .S, and will not likely to bind .L. (Bottom) Embryos were microinjected unilat-erally at the 2-cell or 4-cell stage with 6.6 ng of either Rarγ1.L/S MO (#1) or Rarγ1.S (#2). Injected side is to the right of the dotted line, and is indicated by the magenta β-gal lineage tracer. RARγ1 MO #1 and MO#2 give the same knockdown phenotype on T and Znf703. Fractions represent the portion of embryos displaying the phenotype.
|
|
Supplemental Figure S5. VP16-Rarγ1 mRNA expands Znf703 while DN-Rarγ1 mRNA diminishes Znf703. (A-E) Embryos were injected unilaterally at 2- or 4-cell stage. Injected side is to the right of the dotted line, and is indicated by magenta.β-gal lineage tracer. (A, B, E) 0.2 ng VP 16- Rarγ1 mRNA expands Znf703 dorsally and animally. (C, D) 2 ng DN-Rarγ1 mRNA diminishes Znf703. Embryos are shown at stage 10.5/11 in vegetal (A, C), dorsal (B, D) or animal (E) view.
|
|
znf503 (zinc finger protein 503) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 10.5, vegetal view, dorsal up.
|
|
dhh (desert hedgehog) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 10.5, vegetal view, dorsal up.
|
|
mamdc2 (MAM domain containing 2) gene expression in Xenopus laevis embryo, assayed via in situ hybridization, NF stage 10.5, vegetal view, dorsal up.
|